Literature DB >> 18338653

Hormonal contraceptives for acne management.

Phoebe Rich1.   

Abstract

Acne vulgaris affects 42 million people, more than half of whom are women older than 25 years. Treatment for acne includes oral and topical antibiotics, retinoids, and hormonal therapy in the form of oral contraceptives (OCs). OCs reduce acne lesions by increasing estrogen levels and sex hormone-binding globulins, and by decreasing free testosterone and androgen levels. Several studies have shown that drospirenone, a progestin available in certain OCs, minimizes the potential negative effect the progestin has on acne. Women with moderate acne vulgaris who seek contraception and teenagers with acne who refuse antibiotics or in whom topical antibiotics are ineffective might be candidates for drospirenone-containing OCs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18338653

Source DB:  PubMed          Journal:  Cutis        ISSN: 0011-4162


  4 in total

1.  Hormonal treatment of acne in women.

Authors:  Tobechi L Ebede; Emily L Arch; Diane Berson
Journal:  J Clin Aesthet Dermatol       Date:  2009-12

2.  Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in comparison to one containing levonorgestrel and ethinylestradiol on markers of endocrine function.

Authors:  Ulla M Ågren; Marjatta Anttila; Kristiina Mäenpää-Liukko; Maija-Liisa Rantala; Hilkka Rautiainen; Werner F Sommer; Ellen Mommers
Journal:  Eur J Contracept Reprod Health Care       Date:  2011-09-26       Impact factor: 1.848

3.  Age-dependent endocrine disorders involved in the pathogenesis of refractory acne in women.

Authors:  Simona Ianoşi; Gabriel Ianoşi; Daniela Neagoe; Oana Ionescu; Ovidiu Zlatian; Anca Oana Docea; Corin Badiu; Maria Sifaki; Dimitris Tsoukalas; Aristidis M Tsatsakis; Demetrios A Spandidos; Daniela Călina
Journal:  Mol Med Rep       Date:  2016-11-04       Impact factor: 2.952

4.  Keratosis pilaris and prevalence of acne vulgaris: a cross-sectional study.

Authors:  Juliano Vilaverde Schmitt; Brunno Zeni de Lima; Monique Carolina Meira do Rosário de Souza; Hélio Amante Miot
Journal:  An Bras Dermatol       Date:  2014 Jan-Feb       Impact factor: 1.896

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.